A hazmat fee may apply depending on the amount ordered, as indicated in the list of package sizes.
DMSO: 20mg/mL; H2O: <1mg/mL; EtOH: 4mg/mL
Specific Mammalian target of Rapamycin (mTOR) inhibitor
REVIEW An immunosuppressant drug used to prevent rejection in organ transplantation. Sirolimus inhibits the response to interleukin-2 (IL-2), and thereby blocks activation of T and B cells. In contrast, tacrolimus inhibits the secretion of IL-2. The mode of action of sirolimus is to bind the cytosolic protein FK-binding protein 12 (FKBP12) in a manner similar to tacrolimus. Unlike the tacrolimus-FKBP12 complex which inhibits calcineurin (PP2B), though, the sirolimus-FKBP12 complex inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR Complex1 (mTORC1).
Pagano, Thomas G.; Magnetic Resonance in Chemistry 2005, V43(2), P174-175; (2) Ley, Steven V.; Chemistry--A European Journal 2009, V15(12), P2874-2914.
V?zina C, Kudelski A, Sehgal SN (October 1975). Rapamycin (AY-22,989), a new antifungal antibiotic. J. Antibiot. 28 (10): 721u20136. PMID 1102508.
Pritchard DI (2005). Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discovery Today 10 (10): 688-691. doi:10.1016/S1359-6446(05)03395-7. PMID 15896681.
McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. (June 2002). A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.. Ther Drug Monit. 24 (3): 346-50. PMID 12021624.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.